CASI CASI Pharmaceuticals Inc
Price (delayed)
$2.11
Market cap
$32.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.56
Enterprise value
$37.61M
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is
Highlights
The debt has declined by 3.9% since the previous quarter and by 2.7% year-on-year
The equity has dropped by 92% year-on-year and by 87% since the previous quarter
CASI Pharmaceuticals's quick ratio has plunged by 65% YoY and by 60% from the previous quarter
Key stats
What are the main financial stats of CASI
Market
Valuations
Earnings
Shares outstanding
15.49M
Market cap
$32.69M
Enterprise value
$37.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
17.43
Price to sales (P/S)
1.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
Revenue
$28.54M
Gross profit
$11.15M
Operating income
-$39.43M
Net income
-$39.26M
EBIT
-$38.39M
EBITDA
-$34.94M
Free cash flow
-$29.45M
Per share
Balance sheet
Liquidity
EPS
-$2.56
EPS diluted
-$2.56
Free cash flow per share
-$1.92
Book value per share
$0.12
Revenue per share
$1.86
TBVPS
$3.48
Total assets
$53.67M
Total liabilities
$51.82M
Debt
$18.39M
Equity
$1.85M
Working capital
$3.12M
Debt to equity
9.93
Current ratio
1.09
Quick ratio
0.86
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
-122.4%
Gross margin
39.1%
Net margin
-137.6%
Operating margin
-138.2%
Return on assets
-60.9%
Return on equity
-301.8%
Return on invested capital
-95.5%
Return on capital employed
-222.9%
Return on sales
-134.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CASI stock price
How has the CASI Pharmaceuticals stock price performed over time
Intraday
0.48%
1 week
0%
1 month
-6.22%
1 year
-39.89%
YTD
-25.44%
QTD
-2.31%
Financial performance
How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$28.54M
Gross profit
$11.15M
Operating income
-$39.43M
Net income
-$39.26M
Gross margin
39.1%
Net margin
-137.6%
CASI's operating margin has plunged by 85% YoY
The net margin has dropped by 73% year-on-year
The operating income has plunged by 56% YoY
CASI Pharmaceuticals's net income has decreased by 46% YoY
Growth
What is CASI Pharmaceuticals's growth rate over time
Valuation
What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.43
P/S
1.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
CASI's EPS is down by 27% year-on-year
The equity has dropped by 92% year-on-year and by 87% since the previous quarter
The stock's P/B is 67% above its last 4 quarters average of 10.4
CASI's P/S is 83% below its 5-year quarterly average of 6.7
CASI's revenue is down by 16% YoY
Efficiency
How efficient is CASI Pharmaceuticals business performance
CASI's ROIC has plunged by 82% YoY
The ROA has plunged by 78% YoY
CASI's return on sales has dropped by 69% year-on-year
Dividends
What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CASI.
Financial health
How did CASI Pharmaceuticals financials performed over time
The total assets is 3.6% greater than the total liabilities
CASI Pharmaceuticals's current ratio has plunged by 69% YoY and by 66% from the previous quarter
CASI Pharmaceuticals's quick ratio has plunged by 65% YoY and by 60% from the previous quarter
The equity has dropped by 92% year-on-year and by 87% since the previous quarter
The debt has declined by 3.9% since the previous quarter and by 2.7% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.